SEC Form 4 · accession 0000921895-16-003108
Enveric Biosciences, Inc. · ENVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward O'Donnell
Officer — Chief Financial Officer
Period of report
Jan 28, 2016
Accepted (ET)
Jan 28, 2016 · 7:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000890821
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (Right to Buy)F1 | $6.02 | Jan 28, 2016 | A | 100,000 | A | Jan 28, 2017 | Jan 28, 2022 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The Option vests as follows: (a) as to 33,333 shares of common stock of the Issuer ("Stock), on January 28, 2017, (b) as to a further 33,333 shares of Stock, on January 28, 2018, and (c) as to the remaining 33,334 shares of Stock, on January 28, 2019.